Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Adam Scott Levy, Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold a total of 10,758 shares of common stock on October 13, 2025, for approximately $451,983. The sale comes as the stock trades near its 52-week high of $44.38, having delivered an impressive 252% return year-to-date. According to InvestingPro data, analysts maintain a Strong Buy consensus on the $3.32 billion market cap company.
The sales were executed in two separate transactions. The first involved 7,366 shares sold at a weighted-average price of $41.9021, with individual prices ranging from $41.1362 to $42.1300. The second transaction involved 3,392 shares sold at a weighted-average price of $42.2561, in a range between $42.1600 and $42.3400.
Following these transactions, Levy directly owns 116,865 shares of Mineralys Therapeutics .
The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2023.
In other recent news, Mineralys Therapeutics, Inc. has reported positive subgroup data from its Phase 3 Launch-HTN trial, demonstrating that its aldosterone synthase inhibitor, lorundrostat, significantly reduces blood pressure across diverse patient populations with uncontrolled or resistant hypertension. This data was presented at the American Heart Association Hypertension Scientific Sessions, showcasing efficacy in high-risk groups, including Black/African American adults and older adults. Additionally, Mineralys has completed a public offering, raising approximately $287.5 million, selling over 11 million shares of common stock.
In terms of analyst ratings, H.C. Wainwright has reiterated its Buy rating on Mineralys, citing the potential of lorundrostat, and maintaining a price target of $42.00. Meanwhile, Jefferies has increased its price target for Mineralys from $15.00 to $26.00, though it maintains a Hold rating. The adjustment follows a significant increase in Mineralys’ stock price, influenced by competitor AstraZeneca’s recent performance data. Furthermore, Mineralys has completed enrollment in its Phase 2 EXPLORE-OSA trial for lorundrostat, aimed at evaluating its effectiveness in patients with obstructive sleep apnea and hypertension. Results from this trial are expected in the first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.